Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

The Poc Rsv Testing Market will register a CAGR of more than 7% by 2022

Reportlinker
Posted on: 04 Dec 18
The Poc Rsv Testing Market will register a CAGR of more than 7% by 2022

PR Newswire

NEW YORK, Dec. 4, 2018

NEW YORK, Dec. 4, 2018 /PRNewswire/ -- 107 pages, November 2018

About this market
The growing need for company diagnostics is expected to drive growth in the market. Companion diagnostics are necessary to understand the need of the patient and give personalized medicine. This practice has been trending recently and will thus become a good opportunity to penetrate POC products in the market. Technavio's analysts have predicted that the POC RSV testing market will register a CAGR of more than 7% by 2022.

Read the full report: https://www.reportlinker.com/p05638951

Market Overview
Increase in the incidence and prevalence of RSV infections
The incidence rate of RSV has been high across the globe owing to the ever-increasing air pollution and offsets of the seasons, thus leading to temperature imbalances in the environment. In the US, RSV infections lead to the hospitalization of more than 57,000 patients and two million outpatient visits every year among children below five years.
Product recalls
When products lead to patient injury or fatalities, manufacturers either voluntarily recall them from the market, or regulatory authorities suspend the sales of the faulty devices. Product recalls affect the sales and earnings of a vendor.
For the detailed list of factors that will drive and challenge the growth of the POC RSV testing market during the 2019-2023, view our report.

Competitive Landscape
With the presence of several companies including Abbott and BD, the competitive environment is quite intense. Factors such as the rising demand for POC RSV testing, especially from the developing countries and the expansion of aircraft manufacturing facilities, will provide considerable growth opportunities to POC RSV testing manufactures. Abbott, BD, F. Hoffmann-La Roche, Thermo Fisher Scientific, and bioMérieux are some of the major companies covered in this report.

'With the presence of a considerable number of companies, this market appears to be fragmented. Several POC RSV testing companies are focused on initiating various M&A strategies to develop and market POC products to meet the high volume of demand from across the globe.'

Read the full report: https://www.reportlinker.com/p05638951

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001

View original content:http://www.prnewswire.com/news-releases/the-poc-rsv-testing-market-will-register-a-cagr-of-more-than-7-by-2022-300760049.html

SOURCE Reportlinker

PR Newswire
www.prnewswire.com

Last updated on: 04/12/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.